# A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

> **NCT04729751** · PHASE2 · COMPLETED · sponsor: **Mirum Pharmaceuticals, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Progressive Familial Intrahepatic Cholestasis
- Alagille Syndrome
- Cholestatic Liver Disease

## Interventions

- **DRUG:** Maralixibat

## Key facts

- **NCT ID:** NCT04729751
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-09
- **Primary completion:** 2024-12-17
- **Final completion:** 2024-12-17
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04729751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04729751, "A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04729751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*